Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Marco De Bruyn"'
Autor:
Anneke L. Eerkens, Koen Brummel, Annegé Vledder, Sterre T. Paijens, Marta Requesens, Dominik Loiero, Nienke van Rooij, Annechien Plat, Floris-Jan Haan, Patty Klok, Refika Yigit, Thijs Roelofsen, Natascha M. de Lange, Rie Klomp, David Church, Arja ter Elst, René Wardenaar, Diana Spierings, Floris Foijer, Viktor Hendrik Koelzer, Tjalling Bosse, Joost Bart, Mathilde Jalving, Anna K. L. Reyners, Marco de Bruyn, Hans W. Nijman
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd endometrial cancer (EC) remains unknown. In this investigator-driven, phase I
Externí odkaz:
https://doaj.org/article/1b7aedf643dd44ed914769ada0de8d61
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Genomic instability is a driver and accelerator of tumorigenesis and influences disease outcomes across cancer types. Although genomic instability has been associated with immune evasion and worsened disease prognosis, emerging evidence shows that ge
Externí odkaz:
https://doaj.org/article/c0b5e02b942c476fa734476fa62d514e
Autor:
Etienne Rouleau, Ana Oaknin, Christophe Klein, Alexandra Leary, Sebastien Gouy, Patricia Pautier, Catherine Genestie, Amandine Maulard, Judith Michels, Marco de Bruyn, Emeline Colomba-Blameble, Annechien Plat, Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, Audrey Le Formal, Elodie Edmond, Maëva Moreau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking.Methods We compared the imm
Externí odkaz:
https://doaj.org/article/07f2752f80f74236aa5694863f592740
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have made significant progress in oncotherapy improving survival of patients. However, the benefits are limited to only a small subgroup of patients who could achieve durable responses. Early pr
Externí odkaz:
https://doaj.org/article/2766395661714f37a72f12e6bba44659
Autor:
Ali A. Al-Mubarak, George Markousis Mavrogenis, Xuanxuan Guo, Marco De Bruyn, Mintu Nath, Simon P.R. Romaine, Niels Grote Beverborg, Karla Arevalo Gomez, Sietske N. Zijlstra, Dirk J. van Veldhuisen, Nilesh J. Samani, Adriaan A. Voors, Peter van der Meer, Nils Bomer
Publikováno v:
Redox Biology, Vol 70, Iss , Pp 103046- (2024)
Background: Low selenium concentrations are associated with worse outcomes in heart failure (HF). However, the underlying pathophysiologic mechanisms remain incompletely understood. Therefore, we aimed to contrast serum selenium concentrations to blo
Externí odkaz:
https://doaj.org/article/0c28f97bfc2e48b8b3a335635dabf246
Autor:
Xiaoyu Fan, Marta A. Ważyńska, Arjan Kol, Noemi Perujo Holland, Bruna Fernandes, Sander M. J. van Duijnhoven, Annechien Plat, Hans van Eenennaam, Philip H. Elsinga, Hans W. Nijman, Marco de Bruyn
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Background CD103 is an integrin specifically expressed on the surface of cancer-reactive T cells. The number of CD103+ T cells significantly increases during successful immunotherapy and might therefore be an attractive biomarker for noninva
Externí odkaz:
https://doaj.org/article/42504525a87d43f6acda5c05efb66f5a
Autor:
Marco de Bruyn, Hans Nijman, Annegé Vledder, Jeroen Rovers, Hester Van Zeeburg, Satwinder Singh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fd68770e93ee4da4be4259e459440a3b
Autor:
Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
A higher density of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment, particularly cytotoxic CD8+ T cells, is associated with improved clinical outcome in various cancers. However, local inhibitory factors can suppress T cell activ
Externí odkaz:
https://doaj.org/article/1dd027660af844b49d8b8cf3bd413551
Autor:
Nanda Horeweg, Hagma H. Workel, Dominik Loiero, David N. Church, Lisa Vermij, Alicia Léon-Castillo, Ricki T. Krog, Stephanie M. de Boer, Remi A. Nout, Melanie E. Powell, Linda R. Mileshkin, Helen MacKay, Alexandra Leary, Naveena Singh, Ina M. Jürgenliemk-Schulz, Vincent T. H. B. M. Smit, Carien L. Creutzberg, Viktor H. Koelzer, Hans W. Nijman, Tjalling Bosse, Marco de Bruyn, TransPORTEC consortium
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Tertiary lymphoid structures (TLS) are associated with a reduced risk of cancer recurrence and improved response to immune checkpoint blockade in several tumor types. Here the authors identify L1CAM as a marker for mature TLS and show that the presen
Externí odkaz:
https://doaj.org/article/6cc5d5b840f843b2b959b31b5c279a0f
Autor:
Danique Giesen, Hans van Eenennaam, Hans W. Nijman, Marco de Bruyn, Arjan Kol, Xiaoyu Fan, Marta A. Wazynska, Sander M.J. van Duijnhoven, Annechien Plat, Philip H. Elsinga
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is significantly increased during successful immunotherapy across human malignancies. In this study, we describe the generation and zirconium-89 (89Zr) radio
Externí odkaz:
https://doaj.org/article/f55b3137b2b94aa192c9ac5565a27b1d